FeedworthyAI
Business & Finance

PharmExec articles

pharmexec.com

PharmExec articles

newsBusiness & Finance

Articles100

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Auvelity]]>

<![CDATA[FDA’s Oncologic Drugs Advisory Committee Recognizes Favorable Risk Benefit for Truqap ]]>

<![CDATA[Global Disruptions to the Pharma Supply Chain: Q&A with Jeff Golfman]]>

<![CDATA[FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers]]>

<![CDATA[Asembia ASX26: Payers and the Rising Costs for Cell & Gene Therapies]]>

<![CDATA[Using a Customer-Based Process to Synchronize Sales & Marketing Organizations in Pharma]]>

<![CDATA[Alternative Supply Chain Strategies Companies Should Prioritize]]>

<![CDATA[Asembia ASX26: Adjusting Strategies and Building Relationships: Q&A with Jessica Lovett]]>

<![CDATA[Your Hub Strategy Is Our Strategy: Understanding Patient Support Programs That Adapt, Scale, and Deliver]]>

<![CDATA[Asembia ASX26: The Strain on the Development of Infrastructure for Sustainable C&G Therapy]]>

<![CDATA[Pharmaceutical Executive Daily: Sanofi Appoints Belén Garijo as CEO]]>

<![CDATA[Asembia ASX26: Inizio Launches Next-Generation Hub Services ]]>

<![CDATA[U.S. Prescription Drug Spending Set to Exceed $1 Trillion in 2026: Report ]]>

<![CDATA[Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote]]>

<![CDATA[BMS vs. Moderna vs. Pfizer: The RNA Platform Race]]>

<![CDATA[Asembia ASX26: Strategies for Building Relationships with Pharma Manufacturers]]>

<![CDATA[How Teams Should Quantify and Prepare for Potential Cost Ripple Effects]]>

<![CDATA[MFN and IRA’s Impact of Innovation and Global Strategy: Q&A with Dr. Stella Vnook]]>

<![CDATA[Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher]]>

<![CDATA[Pharmaceutical Risks in the Strait of Hormuz]]>

<![CDATA[Teva Enters $900 Million Agreement to Acquire Emalex]]>

<![CDATA[Asembia's AXS26 Summit: Q&A with Kim Plesnarski]]>

<![CDATA[Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher ]]>

<![CDATA[Asembia's AXS26 Summit: Are Regulatory Policies Impacting Early-Stage Portfolio Planning?]]>

<![CDATA[How are US Regulatory Actions Impacting Pricing?]]>

<![CDATA[Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Breztri]]>

<![CDATA[Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs ]]>

<![CDATA[Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market]]>

<![CDATA[Pharma M&A Roundup: IMG Pharma Acquires Matsumoto Pharmaceutical, Sun Pharma Acquires Organon ]]>

<![CDATA[FDA Approves Breztri for Patients 12 Years and Older with Asthma ]]>

<![CDATA[What Impact Could Recent US Regulatory Actions Have on Global Pricing and Launches?]]>

<![CDATA[Asembia's AXS26 Summit: How is Digital Innovation Transforming Programs for Patient Access?]]>

<![CDATA[Why Ireland Has Become a Strategic Hub for the Global Pharmaceutical Industry]]>

<![CDATA[Asembia AXS26: The Battle for Drug Prices Ahead of the Midterms]]>

<![CDATA[Asembia's AXS26 Summit: How US Regulatory Updates are Impacting Global Launch Strategies]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Caplyta for Adults with Schizophrenia]]>

<![CDATA[FDA Approves Caplyta for Prevention of Schizophrenia in Adults ]]>

<![CDATA[Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics ]]>

<![CDATA[How RFID is Reshaping Health and Wellness Supply Chains: Q&A with Suresh Palliparambil]]>

<![CDATA[Moving Cell and Gene Therapy Towards the Future: Q&A with Maher Masoud]]>

<![CDATA[How Can Pharma Prices be Reduced for Americans Without Impacting Innovation?]]>

<![CDATA[FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie]]>

<![CDATA[FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ]]>

<![CDATA[Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free]]>

<![CDATA[Lessons Learned in the Current Biotech Funding Environment]]>

<![CDATA[The Ron Lanton Report: Where Innovations Happen]]>

<![CDATA[The Long Wait for Rare Disease Treatment Approval: Q&A with Dr. Patricia E. Greenstein]]>

<![CDATA[FDA Approves Otarmeni Gene Therapy for OTOF-Related Hearing Loss]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent]]>

<![CDATA[FDA Approves Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children]]>

<![CDATA[Driving Innovation in Specialty Pharmacy: Q&A Gregory Skalicky from EVERSANA Ahead of Asembia 2026]]>

<![CDATA[FDA Expands Approval for Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria ]]>

<![CDATA[AbbVie Invests $1.4 Billion into New Manufacturing Campus in North Carolina ]]>

<![CDATA[How is the Role of Non-Viral Cell Engineering Technology Growing in Advanced Therapies?]]>

<![CDATA[Pharmaceutical Executive Daily: Idvynso Receives FDA Approval]]>

<![CDATA[FDA Approves Idvynso for Treatment of HIV-1 Infection in Adults]]>

<![CDATA[Amazon One Medical Launches GLP-1 Management Program ]]>

<![CDATA[How Compounding Has Become a Permanent Bridge for Healthcare Access: Q&A with Dr. Nicole Snow]]>

<![CDATA[Top Drugs at Risk of Supply Shortages: Report ]]>

<![CDATA[Pharmaceutical Executive Daily: UnitedHealth Raises Full-Year Profit Forecast ]]>

<![CDATA[Scaling AI in Pharma Requires More Than Algorithms]]>

<![CDATA[What Does it Take to Scale Cell and Gene Therapies from Discovery to Commercialization]]>

<![CDATA[UnitedHealth Raises Profit Forecast Following Improved First Quarter Results ]]>

<![CDATA[Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics]]>

<![CDATA[President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs ]]>

<![CDATA[Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics ]]>

<![CDATA[Addressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomer]]>

<![CDATA[Using AI to Advance Validated Real-World Evidence]]>

<![CDATA[Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning]]>

<![CDATA[Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market]]>

<![CDATA[President Trump Nominates Dr. Erica Schwarts for CDC Leadership Role]]>

<![CDATA[The Turning Point for Oral Biologics: Q&A With Morten Graugaard]]>

<![CDATA[Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD]]>

<![CDATA[Bringing New Delivery Methods to Treatments: Q&A with Richard Lowenthal]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo]]>

<![CDATA[ICER and Verdant Research Publish White Paper Examining FDA’s Accelerated Approval Pathway]]>

<![CDATA[Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request ]]>

<![CDATA[FDA’s Shift Signals a New Era for Data-Driven Drug Development]]>

<![CDATA[What Non-Pricing Factors Are Impacting Biosimilar Decision Making]]>

<![CDATA[How AI Is Transforming Drug Labeling ]]>

<![CDATA[Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program]]>

<![CDATA[Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology]]>

<![CDATA[Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement]]>

<![CDATA[ What Design Choices Made the MajesTEC-3 Trial Clinically Compelling?]]>

<![CDATA[How Are Regulatory Factors Impacting Biosimilars]]>

<![CDATA[A New Standard for Copay Excellence: Q&A with Brian Laird]]>

<![CDATA[Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement]]>

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

<![CDATA[Travere Therapeutics’ Filspari Receives Full FDA Approval ]]>

<![CDATA[How Serious is the Biosimilar Void?]]>

<![CDATA[ Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.]]>

<![CDATA[Building Operational Visibility in Clinical Trials: Q&A with Deepak Prakash]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment]]>

<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

<![CDATA[Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB]]>

<![CDATA[Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer]]>